Matches in SemOpenAlex for { <https://semopenalex.org/work/W1488809246> ?p ?o ?g. }
- W1488809246 endingPage "46" @default.
- W1488809246 startingPage "29" @default.
- W1488809246 abstract "The nitrogen mustard anticancer drugs are widely used for treating many forms of cancer. However, a number of toxic side effects, including secondary tumors, limit their clinical utility. There is strong evidence that the effectiveness for killing cancer cells (cytotoxicity) of these drugs is directly related to the ability of their metabolites to form interstrand DNA crosslinks. These crosslinks are formed by the sequential alkylation of two bases on complementary DNA strands. Other products, including monoalkylated adducts and intrastrand crosslinks are much less cytotoxic, and can mutate the DNA in normal cells leading to the formation of secondary tumors. The nitrogen mustards have a complex DNA-alkylation chemistry. They form monoalkylation adducts at a number of different sites on DNA and the predominant lesions vary between mustards and are strongly modulated by conjugation with DNA-targeting groups including intercalators, minor groove binders, and triplex-forming DNA oligomers. Only a small fraction of the DNA-alkylation events proceed to the formation of the therapeutically useful, highly cytotoxic crosslinks. For this reason there is considerable ongoing research to improve the efficiency of crosslink formation, and reduce the mutagenic effects of the other mustard-induced lesions. The phosphoramide mustard prodrugs including cyclophosphamide and ifosfamide, produce acrolein as a metabolic byproduct. Like the mustards themselves, acrolein has a complex DNA-alkylation chemistry, leading to a diversity of DNA adducts." @default.
- W1488809246 created "2016-06-24" @default.
- W1488809246 creator A5060594038 @default.
- W1488809246 creator A5086404937 @default.
- W1488809246 date "2002-01-01" @default.
- W1488809246 modified "2023-09-23" @default.
- W1488809246 title "DNA-alkylating events associated with nitrogen mustard based anticancer drugs and the metabolic byproduct Acrolein" @default.
- W1488809246 cites W1980701621 @default.
- W1488809246 cites W1981982503 @default.
- W1488809246 cites W1984547408 @default.
- W1488809246 cites W1985155552 @default.
- W1488809246 cites W1985924521 @default.
- W1488809246 cites W1988004447 @default.
- W1488809246 cites W1988139368 @default.
- W1488809246 cites W1992714558 @default.
- W1488809246 cites W1993120989 @default.
- W1488809246 cites W1994053770 @default.
- W1488809246 cites W1998892960 @default.
- W1488809246 cites W1999432535 @default.
- W1488809246 cites W2001840006 @default.
- W1488809246 cites W2005156172 @default.
- W1488809246 cites W2008756156 @default.
- W1488809246 cites W2011914679 @default.
- W1488809246 cites W2012380367 @default.
- W1488809246 cites W2014203783 @default.
- W1488809246 cites W2015774362 @default.
- W1488809246 cites W2016114116 @default.
- W1488809246 cites W2018748618 @default.
- W1488809246 cites W2023008431 @default.
- W1488809246 cites W2023074303 @default.
- W1488809246 cites W2023972044 @default.
- W1488809246 cites W2023980702 @default.
- W1488809246 cites W2026215061 @default.
- W1488809246 cites W2026393863 @default.
- W1488809246 cites W2032265431 @default.
- W1488809246 cites W2037516157 @default.
- W1488809246 cites W2039022474 @default.
- W1488809246 cites W2041496819 @default.
- W1488809246 cites W2045492383 @default.
- W1488809246 cites W2049341534 @default.
- W1488809246 cites W2050966625 @default.
- W1488809246 cites W2055620889 @default.
- W1488809246 cites W2056843068 @default.
- W1488809246 cites W2059678562 @default.
- W1488809246 cites W2063486401 @default.
- W1488809246 cites W2065822483 @default.
- W1488809246 cites W2066779351 @default.
- W1488809246 cites W2066791320 @default.
- W1488809246 cites W2068476420 @default.
- W1488809246 cites W2069297711 @default.
- W1488809246 cites W2076234505 @default.
- W1488809246 cites W2076896674 @default.
- W1488809246 cites W2077389084 @default.
- W1488809246 cites W2080102434 @default.
- W1488809246 cites W2080144605 @default.
- W1488809246 cites W2082302909 @default.
- W1488809246 cites W2090971840 @default.
- W1488809246 cites W2093503231 @default.
- W1488809246 cites W2113969430 @default.
- W1488809246 cites W2118798068 @default.
- W1488809246 cites W2119788707 @default.
- W1488809246 cites W2121706023 @default.
- W1488809246 cites W2132620218 @default.
- W1488809246 cites W2151275048 @default.
- W1488809246 cites W2174123365 @default.
- W1488809246 cites W2950358277 @default.
- W1488809246 cites W2952072637 @default.
- W1488809246 cites W2952670656 @default.
- W1488809246 cites W4316093096 @default.
- W1488809246 cites W4316093101 @default.
- W1488809246 cites W85996255 @default.
- W1488809246 cites W2126916142 @default.
- W1488809246 doi "https://doi.org/10.1016/s1067-568x(02)80004-4" @default.
- W1488809246 hasPublicationYear "2002" @default.
- W1488809246 type Work @default.
- W1488809246 sameAs 1488809246 @default.
- W1488809246 citedByCount "3" @default.
- W1488809246 countsByYear W14888092462022 @default.
- W1488809246 crossrefType "book-chapter" @default.
- W1488809246 hasAuthorship W1488809246A5060594038 @default.
- W1488809246 hasAuthorship W1488809246A5086404937 @default.
- W1488809246 hasConcept C108204754 @default.
- W1488809246 hasConcept C109316439 @default.
- W1488809246 hasConcept C114246631 @default.
- W1488809246 hasConcept C143425029 @default.
- W1488809246 hasConcept C161790260 @default.
- W1488809246 hasConcept C164361826 @default.
- W1488809246 hasConcept C178790620 @default.
- W1488809246 hasConcept C185592680 @default.
- W1488809246 hasConcept C202751555 @default.
- W1488809246 hasConcept C2776694085 @default.
- W1488809246 hasConcept C2776755627 @default.
- W1488809246 hasConcept C2778670039 @default.
- W1488809246 hasConcept C2780422782 @default.
- W1488809246 hasConcept C54355233 @default.
- W1488809246 hasConcept C552990157 @default.
- W1488809246 hasConcept C55493867 @default.
- W1488809246 hasConcept C86803240 @default.